Nazis Chavda¹*, Debabrata Sarkar² and Ronak Chhaya²

¹QA/RA Department, BioAni India Pvt. Ltd., India
²Research and Development Division, BioAni India Pvt. Ltd., India

*Corresponding Author: Ayman Shehata Dawood, Department of Obstetrics and Gynecology, Tanta University, Tanta, Egypt.

Received: July 29, 2026; Published: August 07, 2026

Abstract

Female infertility is a complex reproductive disorder affected by endocrine, metabolic, and oxidative stress-related abnormalities, with polycystic ovary syndrome (PCOS) representing one of the leading causes of anovulatory infertility. Amplifying evidence from randomized clinical trials, systematic reviews, and meta-analyses indicates that insulin resistance, oxidative stress, and chronic inflammation play central roles in compromised follicular development, lowered oocyte capacity, and reduced reproductive results. As a result, therapeutic approaches that focus on these basic mechanisms have obtained significant interest as additional approaches to typical fertility treatments. Myo-inositol has evolved as an effective insulin-sensitizing agent that controls intracellular signalling involved in glucose metabolism, ovarian steroidogenesis, follicular maturation, and ovulation. Clinical studies consistently reveal improvements in menstrual regularity, ovulatory function, oocyte quality, and assisted reproductive technology results, primarily among women with PCOS. N-acetyl-L-cysteine, a precursor of glutathione, uses strong antioxidant and anti-inflammatory impacts by lowering oxidative stress, elevating cellular redox homeostasis, and improving insulin sensitivity. Developing clinical evidence further suggests that N-acetyl-L-cysteine may enhance ovulation, endocrine profiles, and pregnancy results while supporting metabolic approaches in women with infertility. This extensive review precisely examines the current evidence regarding the physiological roles, molecular mechanisms, clinical efficacy, and therapeutic potential of myo-inositol and N-acetyl-L-cysteine in enhancing female fertility. It also discusses the additional actions of these compounds, discusses available clinical evidence, recognizes current limitations, and highlights future research directions to support evidence-based and specific fertility management.

Keywords: Myo-inositol; N-acetyl-L-cysteine; Female infertility; Polycystic ovary syndrome; Insulin resistance; Oxidative stress

References

1. Ghomian N., et al. “Comparison of Pregnancy Rate Between Clomiphene Citrate Alone and Clomiphene Citrate Combined with N-Acetylcysteine in Infertile Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial”. International Journal of Women's Health and Reproduction Sciences3 (2018): 307-312.
2. Mozafari ME., et al. “The Effect of Myo-Inositol and Folic Acid Supplementation on Fertility Outcomes in Infertile Women with Polycystic Ovary Syndrome”. Journal of Ovarian Research1 (2025): 1-10.
3. Sacchinelli A., et al. “The Efficacy of Inositol and N-Acetyl Cysteine Administration (Ovaric HP) in Improving the Ovarian Function in Infertile Women with PCOS with or without Insulin Resistance”. International Journal of Endocrinology 2014 (2014): 141020.
4. Thakker D., et al. “N-Acetylcysteine for Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials”. Obstetrics and Gynecology International 2015 (2015): 817849.
5. Gambioli R., et al. “Myo-Inositol as a Key Supporter of Fertility and Physiological Gestation”. Pharmaceuticals6 (2021): 504.
6. Shang Y., et al. “Antioxidants and Fertility in Women with Ovarian Aging: A Systematic Review and Meta-Analysis”. Redox Biology 78 (2024): 103418.
7. Nemati M., et al. “Effect of Myo-Inositol and N-Acetyl-L-Cysteine on Processed Human Spermatozoa for Use in Modern Methods of Fertility Treatment”. Journal of Shahrekord University of Medical Sciences2 (2020): 53-60.
8. Yifu P. “A Review of Antioxidant N-Acetylcysteine in Addressing Polycystic Ovary Syndrome”. Gynecological Endocrinology1 (2024): 2381498.
9. Regidor PA and Adolf E Schindler. “Myo-Inositol as a Safe and Alternative Approach in the Treatment of Infertile PCOS Women: A German Observational Study”. International Journal of Endocrinology 2016 (2016): 9537632.
10. Saxena S., et al. “Effects of Myo-Inositol and N-Acetylcysteine in Women with Polycystic Ovary Syndrome”. BMC Endocrine Disorders1 (2024): 44.
11. Bevilacqua A., et al. “Myo-Inositol and D-Chiro-Inositol in Improving Reproductive Outcomes in Women with Polycystic Ovary Syndrome: A Systematic Review”. International Journal of Molecular Sciences9 (2023): 7932.
12. Unfer V., et al. “Myo-Inositol Rather than D-Chiro-Inositol Is Able to Improve Oocyte Quality in Intracytoplasmic Sperm Injection Cycles: A Prospective, Controlled, Randomized Trial”. European Review for Medical and Pharmacological Sciences4 (2011): 452-457.
13. Nestler JE., et al. “Ovulatory and Metabolic Effects of D-Chiro-Inositol in the Polycystic Ovary Syndrome”. The New England Journal of Medicine17 (1999): 1314-1320.
14. Nordio M and Emiliano Proietti. “The Combined Therapy with Myo-Inositol and D-Chiro-Inositol Reduces the Risk of Metabolic Disease in PCOS Women”. European Review for Medical and Pharmacological Sciences5 (2012): 575-581.
15. Genazzani AR., et al. “Myo-Inositol Administration Positively Affects Hyperinsulinemia and Hormonal Parameters in Overweight Patients with Polycystic Ovary Syndrome”. Gynecological Endocrinology3 (2008): 139-144.
16. Facchinetti F., et al. “Short-Term Effects of Myo-Inositol in Women with Polycystic Ovary Syndrome: A Randomized Clinical Trial”. European Review for Medical and Pharmacological Sciences3 (2013): 298-304.
17. Laganà AS., et al. “Inositol in Polycystic Ovary Syndrome: Restoring Fertility Through a Physiological Approach”. International Journal of Endocrinology 2018 (2018): 9528050.
18. Chiu TTY., et al. “Myo-Inositol in Oocyte Development and Fertility: A Systematic Review”. Reproductive Biology and Endocrinology1 (2017): 1-12.
19. Artini PG., et al. “Role of Myo-Inositol and Antioxidants in Improving Female Reproductive Function”. Gynecological Endocrinology6 (2017): 464-467.
20. Carlomagno G and Vittorio Unfer. “Inositol Safety: Clinical Evidence and Future Perspectives”. European Review for Medical and Pharmacological Sciences8 (2011): 931-936.
21. Regidor P A., et al. “Management of Women with Polycystic Ovary Syndrome Using Myo-Inositol: Clinical Evidence and Future Perspectives”. International Journal of Endocrinology 2018 (2018): 8796503.
22. Costantino D., et al. “Metabolic and Hormonal Effects of Myo-Inositol in Women with Polycystic Ovary Syndrome: A Double-Blind Trial”. European Review for Medical and Pharmacological Sciences2 (2009): 105-110.
23. Papaleo E., et al. “Myo-Inositol in Patients with Polycystic Ovary Syndrome: A Novel Method for Ovulation Induction”. Gynecological Endocrinology12 (2007): 700-703.
24. Minozzi M., et al. “The Combined Use of Myo-Inositol and Folic Acid in Women with Polycystic Ovary Syndrome Undergoing Assisted Reproduction”. European Review for Medical and Pharmacological Sciences4 (2011): 509-514.
25. Unfer V and Antonio Simone Laganà. “Myo-Inositol: From Basic Science to Clinical Practice in Polycystic Ovary Syndrome”. International Journal of Endocrinology 2017 (2017): 6846285.

Citation

Citation: Nazis Chavda., et al. “Role of Myo-Inositol and N-Acetyl-L-Cysteine in Improving Female Fertility: A Comprehensive Review". Acta Scientific Women's Health 8.6 (2026): 45-53.

Copyright

Copyright: © 2026 Nazis Chavda., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.